Herein, we show that SEL24-B489 specifically inhibits PIM- and FLT3-ITD- related pathways and exhibits significantly broader anti-tumor activity in AML models than selective FLT3-ITD or PIM inhibitors, underscoring its therapeutic potential for the treatment of AML. This evidence concerns the gene PIM1 and acute myeloid leukemia.